A consensus - Hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 36, 2008, Pages 13538-13543

  Chen, Ming Wei ^a,c   Cheng, Ting Jen Rachel ^a   Huang, Yaoxing ^b   Jan, Jia Tsrong ^a   Ma, Shiou Hwa ^a   Yu, Alice L ^a   Wong, Chi Huey ^a,d   Ho, David D ^a,b,e  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b ROCKEFELLER UNIVERSITY   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

^e AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; PLASMID DNA; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; DRUG EFFECT; ELECTROPORATION; FEMALE; GENE INSERTION; HUMORAL IMMUNITY; IC 50; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOTYPING; VACCINE PRODUCTION; VIRION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; GENE EXPRESSION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; PHYLOGENY; PLASMIDS; TITRIMETRY; VACCINES, DNA;

AVES; MUS; ORTHOMYXOVIRIDAE;

EID: 51649100250     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0806901105     Document Type: Article

References (39)

1. Li KS, et al. (2004) Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209-213.
2. Ungchusak K, et al. (2005) Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352:333-340.
3. Beigel JH, et al. (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-1385.
4. Kuiken T, et al. (2006) Host species barriers to influenza virus infections. Science 312:394-397.
5. Osterholm MT (2005) Preparing for the next pandemic. N Engl J Med 352:1839-1842.
6. Neuzil KM, et al. (2006) Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194:1032-1039.
7. Couch RB, Keitel WA, Cate TR (1997) Improvement of inactivated influenza virus vaccines. J Infect Dis 176 Suppl 1:S38-S44.
8. Hoffmann E, et al. (2002) Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci USA 99:11411-11416.
9. Ghendon YZ, et al. (2005) Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 23:4678-4684.
10. Ehrlich HJ, et al. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 359:2573-2584.
11. Swayne DE, Lee CW, Spackman E (2006) Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathol 35:141-146.
12. Lu X, et al. (2006) Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593.
13. Bresson JL, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367:1657-1664.
14. Treanor JJ, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
15. Gao W, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80:1959-1964.
16. Hoelscher M, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481.
17. Kong WP, et al. (2006) Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci USA 103:15987-15991.
18. Laddy DJ, et al. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25:2984-2989.
19. Luxembourg A, Evans CF, Hannaman D (2007) Electroporation-based DNA immunization: Transition to the clinic. Exp Opin Biol Ther 7:1647-1664.
20. Lee CW, Senne DA, Suarez DL (2006) Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens. Clin Vaccine Immunol 13:395-402.
21. Nicholson KG, Wood JM, Zambon M (2003) Influenza. Lancet 362:1733-1745.
22. World Health Organization (2008) Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines. Available at http://www.who.int/csr/disease/avian_influenza/ guidelines/H5VaccineVirusUpdate20080214.pdf. Accessed February 2008.
23. Goetz RM, Fuglsang A (2005) Correlation of codon bias measures with mRNA levels: Analysis of transcriptome data from Escherichia coli. Biochem Biophys Res Comm 327:4-7.
24. Holm L (1986) Codon usage and gene expression. Nucleic Acids Res 14:3075-3087.
25. Wang S, et al. (2006) Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studies by codon-optimized HA DNA vaccines. J Virol 80:11628-11637.
26. Gao F, et al. (2003) Consensus and ancestral state HIV vaccines. Science 299:1517-1518.
27. Gaschen B, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
28. Kothe DL, et al. (2006) Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352:438-449.
29. Laddy DJ, Weiner DB (2006) From plasmids to protection: A review of DNA vaccines against infectious diseases. Intl Rev Immunol 25:99-123.
30. Lalor PA, et al. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197:1643-1652.
31. Liu J, Kjeken R, Mathiesen I, Barouch DH (2008) Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 82:5643-5649.
32. Luxembourg A, et al. (2008) Potentiation of an anthrax DNA vaccine with electroporation. Vaccine, 10.1016/j.vaccine. 2008.03.064.
33. Temperton NJ, et al. (2007) A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Resp Diseases 1:105-112.
34. Kistner O, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028-6036.
35. Hoelscher M, et al. (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 197:1185-1188.
36. Chen H, et al. (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proc Natl Acad Sci USA 103:2845-2850.
37. Wang S, et al. (2008) The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26:2100-2110.
38. Laddy DJ, et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensusDNAantigens. PLoS One 3:e2517.
39. Hall TA (1999) Bioedit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acid Symp Ser 41:95-98.